Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on December 10, 2007

Circulation. 2007
Published online before print December 10, 2007, doi: 10.1161/CIRCULATIONAHA.107.728550
A more recent version of this article appeared on January 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
117/1/43    most recent
CIRCULATIONAHA.107.728550v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Heerebeek, L.
Right arrow Articles by Paulus, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Heerebeek, L.
Right arrow Articles by Paulus, W. J.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Diabetes Complications
*Heart Failure
Related Collections
Right arrow Contractile function
Right arrow Cardio-renal physiology/pathophysiology
Right arrow Congestive
Right arrow Hypertrophy
Right arrow Type 1 diabetes
Right arrow Type 2 diabetes
Right arrowRelated Article

Submitted on July 17, 2007
Accepted on October 26, 2007

Diastolic Stiffness of the Failing Diabetic Heart. Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension

Loek van Heerebeek MD, Nazha Hamdani PhD, M. Louis Handoko MD, Ines Falcao-Pires PhD, René J. Musters PhD, Koba Kupreishvili MD, Alexander J.J. Ijsselmuiden MD, PhD, Casper G. Schalkwijk PhD, Jean G.F. Bronzwaer MD, PhD, Michaela Diamant MD, PhD, Attila Borbély MD, Jolanda van der Velden PhD, Ger J.M. Stienen PhD, Gerrit J. Laarman MD, PhD, Hans W.M. Niessen MD, PhD, and Walter J. Paulus MD, PhD*

From the Departments of Physiology (L.v.H., N.H., M.L.H., I.F-P., R.J.M., A.B., J.v.d.V., G.J.M.S., W.J.P.), Cardiology (J.G.F.B.), Endocrinology (M.D.), and Pathology and Surgery (K.K, H.W.M.N.), Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, the Netherlands; Department of Cardiology (A.J.J.I, G.J.L.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands; and Department of Internal Medicine (C.G.S.), University of Maastricht, Maastricht, the Netherlands.

* To whom correspondence should be addressed. E-mail: wj.paulus{at}vumc.nl.

Background—Excessive diastolic left ventricular stiffness is an important contributor to heart failure in patients with diabetes mellitus. Diabetes is presumed to increase stiffness through myocardial deposition of collagen and advanced glycation end products (AGEs). Cardiomyocyte resting tension also elevates stiffness, especially in heart failure with normal left ventricular ejection fraction (LVEF). The contribution to diastolic stiffness of fibrosis, AGEs, and cardiomyocyte resting tension was assessed in diabetic heart failure patients with normal or reduced LVEF.

Methods and Results—Left ventricular endomyocardial biopsy samples were procured in 28 patients with normal LVEF and 36 patients with reduced LVEF, all without coronary artery disease. Sixteen patients with normal LVEF and 10 with reduced LVEF had diabetes mellitus. Biopsy samples were used for quantification of collagen and AGEs and for isolation of cardiomyocytes to measure resting tension. Diabetic heart failure patients had higher diastolic left ventricular stiffness irrespective of LVEF. Diabetes mellitus increased the myocardial collagen volume fraction only in patients with reduced LVEF (from 14.6±1.0% to 22.4±2.2%, P<0.001) and increased cardiomyocyte resting tension only in patients with normal LVEF (from 5.1±0.7 to 8.5±0.9 kN/m2, P=0.006). Diabetes increased myocardial AGE deposition in patients with reduced LVEF (from 8.8±2.5 to 24.1±3.8 score/mm2; P=0.005) and less so in patients with normal LVEF (from 8.2±2.5 to 15.7±2.7 score/mm2, P=NS).

Conclusions—Mechanisms responsible for the increased diastolic stiffness of the diabetic heart differ in heart failure with reduced and normal LVEF: Fibrosis and AGEs are more important when LVEF is reduced, whereas cardiomyocyte resting tension is more important when LVEF is normal.


Key words: diastole • diabetes mellitus • heart failure • collagen • myocytes


Related Article:

Clinical Summaries
Circulation 2008 117: 1-3. [Full Text]



This article has been cited by other articles:


Home page
CirculationHome page
K. A. Connelly, R. E. Gilbert, and H. Krum
Letter by Connelly et al Regarding Article, "Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension"
Circulation, June 10, 2008; 117(23): e483 - e483.
[Full Text] [PDF]